Pharmacokinetics of pazufloxacin in buffalo calves after single subcutaneous administration

S K SHARMA; ADITI ADITI

doi:10.56093/ijans.v85i3.47237

Authors

S K SHARMA Professor-cum-Head, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab 141 004 India
ADITI ADITI Rural Veterinary Officer, Civil Veterinary Hospital, Binjo, Punjab

https://doi.org/10.56093/ijans.v85i3.47237

Keywords:

Buffalo calves, Pazufloxacin, Pharmacokinetics, Urinary excretion

Abstract

The pharmacokinetics and urinary excretion of pazufloxacin was investigated in buffalo calves following a single subcutaneous administration (5 mg/kg b.wt.). Pharmacokinetic analysis of disposition data indicated that subcutaneous administration data were best described by 1-compartment open model. The peak plasma levels of pazufloxacin were 1.12±0.05 μg/ml at 45 min and the drug was detected up to 16 h. The absorption half-life and elimination half-life were 0.26±0.04 h and 3.01±0.18h, respectively. The apparent volume of distribution and total body clearance were 2.96±0.20 L/kg and 0.67±0.02 L/kg/h, respectively. The urinary excretion of pazufloxacin in 24 h was 23.8±2.30 % of total administrated dose. From the data of surrogate markers (AUC/MIC, Cmax/MIC), it was determined in the buffalo calves that when administered by the subcutaneous route at 5 mg/kg, pazufloxacin is likely to be effective against bacterial isolates with MIC < 0.05 μg/ml.

Downloads

Download data is not yet available.

References

Baggot J D. 1977. Principles of pharmacokinetics. Principles of Drug Disposition in Domestic Animals. pp. 144–89. WB Saunders Co. Philadelphia.

Craig W A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26: 1–10. DOI: https://doi.org/10.1086/516284

Gibaldi M and Perrier D. 1982. Pharmacokinetics. Marcell Dekker Inc., New York. DOI: https://doi.org/10.1201/b14095

Lode H, Borner K and Koeppe P. 1998. Pharmacodynamics of fluoroquinolones. Clinical Infectious Diseases 27: 33–39. DOI: https://doi.org/10.1086/514623

Lou S, Li W and Hu Q. 2007. Influence of cefoperazone and azithromycin on the pharmacokinetics of pazufloxacin in rats. European Journal of Drug Metabolism and Pharmacokinetics 32(4): 219–23. DOI: https://doi.org/10.1007/BF03191007

Mitsuyama J, Takahata M, Yamashiro Y, Kitayama R, Muratani T, Matsumura N, Nakata M, Fukuta T, Yamada H, Maehana J, Hamada S, Sugiyama H, Shimakura M, Minami S, Watanabe Y and Narita H. 1999. Antibacterial activity of a new injectable quinolone, pazufloxacin mesilate (PZFX mesilate), in vitro and in vivo. Japanese Journal of Chemotherapy 47: 37–64.

Nakata M, Yamashiro Y, Shimakura M, Takahata M, Minami S, Watanabe Y and Narita H. 1999. Pharmacokinetics of pazufloxacin mesilate in experimental animals. Japanese Journal of Chemotherapy 47: 65–75.

Nomura N, Mitsuyama J, Furuta Y, Yamada H, Nakata M, Fukuda T, Yamada H, Takahata M and Minami S. 2002. In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone. The Japanese Journal of Antibiotic 55(4): 412–39.

Pathania R and Sharma S K. 2010. Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. Research in Veterinary Science 89(1): 108–12. DOI: https://doi.org/10.1016/j.rvsc.2010.01.015

Phapale P B, Lee H W, Kim S, Lim M, Kale D D, Lee J M, Park J H, Moon S and Yoon Y. 2010. Analysis of pazufloxacin mesilate in human plasma and urine by LC with fluorescence and UV detection and its application to pharmacokinetic study. Chromatographia 71: 101–06. DOI: https://doi.org/10.1365/s10337-009-1408-1

Raipuria M, Dumka V K and Sandhu H S. 2007. Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves. Veterinary Research Communications 31: 1013–20. DOI: https://doi.org/10.1007/s11259-007-3343-7

Sappal R, Chaudhary R K, Sandhu H S and Sidhu P K. 2009. Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (Bubalus bubalis). Veterinary Research Communications 33: 659–67. DOI: https://doi.org/10.1007/s11259-009-9215-6

Sharma S K, Aditi and Shah Ahsan Ul Haq. 2014. Influence of Escherichia coli lipopolysaccharide induced fever on the plasma kinetics of pazufloxacin in buffalo calves. Indian Journal of Animal Sciences 84(2): 166–69.

Shojaee Aliabadi F and Lees P. 2000. Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation. International Journal of Antimicrobial Agents 14: 307–13. DOI: https://doi.org/10.1016/S0924-8579(00)00142-4

Toutain P L and Bousquet-Melou A. 2004. Volumes of distribution. Journal of Veterinary Pharmacology and Therapeutics 27: 441–53. DOI: https://doi.org/10.1111/j.1365-2885.2004.00602.x

Toutain P L and Lees P. 2004. Integration and modeling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 27: 467–77. DOI: https://doi.org/10.1111/j.1365-2885.2004.00613.x

Turnidge J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58: 29–36. DOI: https://doi.org/10.2165/00003495-199958002-00006

Walker R D. 2000. Fluoroquinolones. Antimicrobial Therapy in Veterinary Medicine. 3rd edn, pp. 315–38. (Eds) Prescott J F, Baggot D and Walker R D. Iowa State University Press, Ames, USA.

Zhanel G G, Ennis K, Vercaigne L, Walkty A, Gin A S, Embil J, Smith H and Hoban D J. 2002. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62: 13–59. DOI: https://doi.org/10.2165/00003495-200262010-00002

Zhanel G G, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin A M, Gin A S, Rubinstein E and Hoban D J. 2006. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treatment in Respiratory Medicine 5: 437–65. DOI: https://doi.org/10.2165/00151829-200605060-00009